Craig R. Stapleton

Craig R. Stapleton discloses dealings in 3 companies, chiefly Avadel Pharmaceuticals PLC, Abercrombie & Fitch Co /DE/ and Sonomawest Holdings Inc. Over a trading history stretching from 14 November 2006 to 1 August 2018, the count stands at 62 filings.

The open-market side counts 23 purchases for €4.8M alongside 4 sales for €3.0M. Taken together, the purchases exceed the sales by €1.8M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 18 share grants and 2 option exercises.

In size, the median ticket on the buying side is €158k. On 12 out of 13 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 7 purchases with a full 90-day history, the hit rate stands at 43% and the median 90-day move at -1.9%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 2 August 2018: a share grant, in Avadel Pharmaceuticals PLC. The last insider purchase was made public on 19 December 2017, 3,246 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.